Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure
A Randomized, Double-Blind, Placebo-Controlled Trial
Piotr Ponikowski, MD, PhD*,3,6,
Stefan D. Anker, MD, PhD , ,1,3,4,6,
Joanna Szachniewicz, MD*,
Darlington Okonko, BSc, MRCP,2,
Mark Ledwidge, PhD ,
Robert Zymlinski, MD*,
Enda Ryan, MRCP,
Scott M. Wasserman, MD||,
Nigel Baker, MSc||,5,
Dylan Rosser, BSc||,5,
Stuart D. Rosen, MD,
Philip A. Poole-Wilson, MD,
Waldemar Banasiak, MD, PhD*,
Andrew J.S. Coats, DM¶,3,4 and
Ken McDonald, MD,3,*
* Cardiac Department, Military Hospital, Wroclaw, Poland
Clinical Cardiology, National Heart and Lung Institute, Imperial College London, London, England
Division of Applied Cachexia Research, Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany
Department of Cardiology, St. Vincent’s University Hospital, Elm Park, Dublin, Ireland
|| Amgen Limited, 240 Cambridge Science Park, Cambridge, England
¶ Faculty of Medicine, University of Sydney, Sydney, Australia.
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Change From Baseline in Measures of Exercise Tolerance and Duration Over Time
(A) Mean change in peak VO
2 over time, p = 0.248 for darbepoetin alfa versus placebo. (B) Mean change in total VO
2 over time, p = 0.134 for darbepoetin alfa versus placebo. (C) Mean change in exercise duration over time, p = 0.074 for darbepoetin alfa versus placebo. Data are mean ± SE.
|
|
View larger version (7K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Individual Changes From Baseline to Week 27 in Hemoglobin Concentration Relative to the Change From Baseline in Exercise Duration
Multiple values may occur in the same location. Placebo: change in VO
2 = 16.5 x change in Hb – 74.8; darbepoetin alfa: change in VO
2 = 158 x change in Hb – 310. Solid line = placebo; dashed line = darbepoetin alfa.
|
|
|
